Higher baseline ALT,lower baseline HBV DNA levels and the HBeAg decline more than 50% at the early stage of treatment(with EVR) are significant predictors of HBeAg seroconversion for Lamivudine treatment.

• 治疗前,较高的ALT水平、较低的HBVDNA定量值及出现早期病毒应答是影响拉米夫定治疗慢性乙肝疗效的主要因素。